Denali Therapeutics (DNLI) Q2 2026 earnings — TrendMatrix coverage
Reported
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. How we score · Full disclosure
Key numbers
- Reported EPS
- -$0.68
- Estimate
- -$0.52
- Surprise
- -29.9%
- Revenue (period 2026-06-30)
- $3.6M
- Score today
- 5.4/10
Revenue source: mixed.
How the report landed
Denali Therapeutics (DNLI) reported a wider loss than forecast — diluted EPS of -$0.68 against the -$0.52 estimate (a 29.9% shortfall).
Where TrendMatrix's rating stands now
TrendMatrix currently rates DNLI Sell at 5.4/10; no pre/post engine snapshot brackets this report.
3 of the last 4 quarters beat the estimate; this quarter's -29.9% surprise compares with a -9.5% four-quarter average. Next scheduled report: 2026-11-05.
What argues against it
- Concentration risk — Pipeline: tividenofusp alfa
- Quality below floor (1.8 < 4.0)
- Momentum score 2.6/10 — below 4.5 minimum
This section and the ones below it reflect TrendMatrix’s latest engine read — they update after the report date and are not frozen to it.
The levels TrendMatrix's engine tracks
- Current price
- $22.31
- Price target
- $32.18
- Stop
- $21.48
- Upside to target
- +44.2%
- Reward-to-risk
- 5.5:1
Model outputs from TrendMatrix’s engine as of 2026-09-04 — shown for context, not personalized investment advice.
DNLI at TrendMatrix's latest read
Healthcare earnings trade on pipeline and payer dynamics as much as the quarter itself; a beat or miss is weighed against trial and reimbursement news.
- Industry
- Biotechnology
- Market cap
- $3.64B
- P/E (fwd)
- -9.4
- 52-week range
- $12.58–$27.30
- Off 52-week high
- 18.3%
- RSI (14)
- 34
- Volume vs avg
- 0.41×
- Score today
- 5.4/10